NEWS
NEWS
Global clinical trials take a major hit from pandemic, with endocrine targeted tests worst hit
Clinical trial enrollment has dropped massively across the world with endocrine and cardiovascular tests being the hardest hit. This is according...
To avoid DTC dips and communication snafus, pharma marketing shifts amid COVID-19 crisis
Pharma marketing, like the rest of the ad industry, is in a state of flux brought on by the COVID-19 pandemic. Concerns and debates are swirling...
Trump tries to lure CureVac to make a ‘U.S. vaccine,’ but German government steps in
It’s a pretty extraordinary story that started off with a CEO exiting a biotech and has now become about the U.S. president allegedly wanting to...
Biogen cracks down on travel after 3 execs test positive for coronavirus
The novel coronavirus has hit home at Biogen, where three executives who traveled to a headquarters management meeting have tested positive for...
Why FDA can’t disclose the first coronavirus-related drug shortage
Around 10 PM ET last night, the FDA said that it is aware of a drug shortage related to an active pharmaceutical ingredient (API) manufacturer...
The top 10 ad spenders in Big Pharma for 2019
Direct-to-consumer drug ads tend to strike a dissonant chord. However, fan and foe can count on one thing: Prescription DTC advertising is here...
States reject drug wholesalers’ $18B opioid settlement offer: WSJ
After years of opioid litigation and a multibillion-dollar settlement offer from the nation's top drug distributors, nearly two dozen U.S. states...
The 20 most expensive pharmacy drugs in the U.S. in 2020, from fallen blockbusters to new orphan meds
Drug pricing remains a hot topic, and a new report offers some reasons: The most expensive drugs sold at pharmacies can cost as much as a luxury...
Servier begins manslaughter trial over weight loss drug
French pharma Servier begins trial today, as the company stands accused of manslaughter and deceit over a diabetes weight loss drug linked to as...
Amgen, Novartis scrap Alzheimer’s studies — is BACE finally dead or will Biogen and Eisai carry on?
Тhe BACE theory of controlling Alzheimer’s died with failed pivotal projects at Merck, Eli Lilly and their partners at AstraZeneca. Now Amgen and...
True innovation or just later to market? German agency questions benefits of new drugs
When a new drug is approved, the developer usually trumpets its ability to fill an unmet medical need. But a German agency that evaluates...
The top 10 drug launches of 2019
Cancer is probably the most sought-after indication in the biopharma world, but it’s missing from 2019's class of top drug launches. Instead,...